Chronic Myelogenous Leukemia in Children

Introduction

Chronic Myelogenous Leukemia (CML) is a rare form of leukemia that affects the myeloid lineage of blood cells. It is characterized by the presence of the Philadelphia chromosome, which results from a reciprocal translocation between chromosomes 9 and 22, resulting in the formation of the BCR-ABL fusion gene. CML in children is relatively uncommon, accounting for approximately 2-3% of all childhood leukemias.

Epidemiology and Etiology

CML has an annual incidence of 1 to 2 cases per million children. It can occur at any age but is more commonly seen in adults. The median age at diagnosis in children is around 10 years. The etiology of CML is unknown, but ionizing radiation exposure has been identified as a potential risk factor.

Pathogenesis

The BCR-ABL fusion gene, resulting from the Philadelphia chromosome, leads to the production of a constitutively active tyrosine kinase enzyme. This enzyme promotes uncontrolled proliferation and survival of myeloid cells, ultimately leading to the development of CML. The BCR-ABL protein also plays a role in inhibiting apoptosis, increasing genomic instability, and promoting angiogenesis.

Clinical Presentation

CML in children typically presents in the chronic phase, characterized by the following signs and symptoms:

Fatigue
Weakness
Weight loss
Abdominal fullness or discomfort (due to an enlarged spleen)
Fever
Night sweats
Bone pain

In some cases, the disease may be discovered incidentally during routine blood tests, which may reveal an elevated white blood cell count, basophilia, or other abnormalities.

Diagnosis

The diagnosis of CML in children typically involves the following tests:

Complete Blood Count (CBC): This test may reveal an elevated white blood cell count, often with a predominance of immature myeloid cells (blasts) and basophils.
Bone Marrow Aspiration and Biopsy: This is essential for confirming the diagnosis and assessing the percentage of blasts in the bone marrow.
Cytogenetic Analysis: This test is used to detect the presence of the Philadelphia chromosome (t(9;22)) or the BCR-ABL fusion gene.
Fluorescence In Situ Hybridization (FISH): This technique can also be used to detect the BCR-ABL fusion gene.
Reverse Transcription-Polymerase Chain Reaction (RT-PCR): This molecular test can detect and quantify the level of BCR-ABL transcripts, which is useful for monitoring response to treatment.

Treatment

The treatment of CML in children has undergone significant advancements with the introduction of tyrosine kinase inhibitors (TKIs). The goal of treatment is to achieve and maintain a deep molecular response, which is associated with improved long-term outcomes.

Tyrosine Kinase Inhibitors (TKIs)

TKIs are the mainstay of treatment for CML in children. These targeted therapies inhibit the activity of the BCR-ABL tyrosine kinase, leading to a reduction in the number of leukemic cells. The most commonly used TKIs in children include:

Imatinib: Imatinib was the first TKI approved for the treatment of CML in children. It has shown excellent efficacy and is generally well-tolerated.
Dasatinib: Dasatinib is a second-generation TKI that may be used in cases of imatinib resistance or intolerance.
Nilotinib: Nilotinib is another second-generation TKI that can be used as an alternative to imatinib or dasatinib.

The choice of TKI depends on several factors, including the patient's age, disease phase, treatment response, and potential side effects.

Stem Cell Transplantation

In certain cases, allogeneic hematopoietic stem cell transplantation (HSCT) may be considered for children with CML. HSCT is a potentially curative option but carries significant risks, including graft-versus-host disease (GVHD) and treatment-related mortality. The decision to pursue HSCT is based on factors such as the patient's age, disease phase, response to TKI therapy, and the availability of a suitable donor.

Monitoring and Follow-up

Regular monitoring of patients with CML is essential to assess treatment response and detect any potential complications or disease progression. This typically involves:

Complete Blood Count (CBC): Performed regularly to monitor blood cell counts and detect any abnormalities.
Molecular Testing (RT-PCR): Used to quantify the level of BCR-ABL transcripts and monitor the depth of molecular response to treatment.
Bone Marrow Aspiration and Biopsy: May be performed periodically to assess the status of the disease and monitor for any cytogenetic or molecular changes.

Additionally, patients should be closely monitored for potential side effects of treatment, such as myelosuppression, fluid retention, and other organ-specific toxicities.

Prognosis and Long-term Outcomes

The prognosis for children with CML has significantly improved with the advent of TKI therapy. Children who achieve and maintain a deep molecular response have excellent long-term outcomes, with survival rates approaching those of the general population.

However, factors such as the presence of high-risk cytogenetic or molecular abnormalities, resistance to TKI therapy, and disease progression to the accelerated or blast phase can negatively impact prognosis.

Long-term follow-up is essential to monitor for potential late effects of treatment, such as fertility issues, secondary malignancies, and cardiovascular complications. Adherence to treatment and regular monitoring are crucial for optimal outcomes.

Conclusion

CML in children is a rare but treatable condition. Early diagnosis and appropriate treatment with TKIs have significantly improved outcomes for these patients. Ongoing research and clinical trials are aimed at further refining treatment strategies, developing new targeted therapies, and improving long-term quality of life for children with CML.

Case Studies

Case 1: Successful Treatment with Imatinib

A 7-year-old girl presented with fatigue, abdominal discomfort, and mild fever. Laboratory tests revealed an elevated white blood cell count of 250,000/μL, with predominant myeloid cells and basophilia. Bone marrow aspiration and cytogenetic analysis confirmed the diagnosis of CML in the chronic phase, with the presence of the Philadelphia chromosome.

The patient was started on imatinib therapy at a dose of 260 mg/m2 daily. After 3 months of treatment, she achieved a complete cytogenetic response (CCyR), and by 12 months, she had achieved a major molecular response (MMR) with a BCR-ABL transcript level of 0.01%.

The patient continued imatinib therapy and remained in sustained deep molecular remission for over 5 years. She experienced minimal side effects, with occasional mild periorbital edema and muscle cramps. Regular monitoring and adherence to treatment were crucial in maintaining her excellent response.

Case 2: Resistance to Imatinib and Successful Transition to Dasatinib

A 12-year-old boy was diagnosed with CML in the chronic phase after presenting with fatigue, night sweats, and an enlarged spleen. He was started on imatinib therapy, but after 18 months, his response plateaued at a suboptimal level, with a BCR-ABL transcript level of 1%.

Mutational analysis revealed the presence of the T315I mutation, which confers resistance to imatinib. The decision was made to switch the patient to dasatinib therapy at a dose of 60 mg/m2 once daily.

Within 6 months of starting dasatinib, the patient achieved a deep molecular response, with undetectable BCR-ABL transcripts. He experienced mild side effects, including occasional pleural effusions and mild elevations in liver enzymes, which were managed with supportive care.

The patient has remained in sustained deep molecular remission for over 3 years on dasatinib therapy, highlighting the importance of monitoring treatment response and considering alternative TKIs in cases of resistance or suboptimal response.

References

Soverini, S., Mancini, M., Bavaro, L., Cavo, M., & Martinelli, G. (2018). Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. Molecular Cancer, 17(1), 49.
Millot, F., Traore, P., Guilhot, J., Nelken, B., Leblanc, T., Leverger, G., ... & Guilhot, F. (2005). Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia. Pediatrics, 116(1), 140-143.
Millot, F., Baruchel, A., Guilhot, J., Petit, A., Leblanc, T., Bertrand, Y., ... & Leverger, G. (2017). Imatinib is superior to a combination of chemotherapy and stem cell transplantation in children with Philadelphia chromosome-positive acute lymphoblastic leukemia: Final results of the FRALLE 2005-01 randomized study. Journal of Clinical Oncology, 35(15_suppl), 10510-10510.
Zwaan, C. M., Rizzari, C., Lehrnbecher, T., Möricke, A., Aricò, M., Castagnola, E., ... & Groll, A. H. (2020). Recommendations for the management of children with chronic myeloid leukemia: An International Society of Paediatric Oncology (SIOP) Chronic Malignancy Working Group report. Pediatric Blood & Cancer, 67(11), e28541.
Hijiya, N., & Suttorp, M. (2019). How I treat chronic myeloid leukemia in children and adolescents. Blood, 133(5), 441-451.